C-21 hydroxylated FK-506 antagonist
US5225403A · kind A · utility
15Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 1991 |
| Grant date | Jul 6, 1993 |
| Priority date | — |
| Expiry date | Jun 25, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/898
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described is a process for producing a new FK-506 antagonist agent, a C-21 hydroxylated analog of FR-900520 under novel fermentation conditions utilizing the novel microorganism, Streptomyces hygroscopicus (Merck Culture Collection MA 6832) ATCC No. 55166. The macrolide antagonist is useful in preventing and/or counteracting accidental or inadvertent FK-506 overdosage in an FK-506 therapeutic program designed to prevent autoimmune diseases or human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.